One case of eye graft-versus-host disease with corneal perforation and fungal keratitis

doi:10.3877/cma.j.issn.2095-2007.2024.02.006

Abstract

Zhongcheng Shen, Fanghan Li. One case of eye graft-versus-host disease with corneal perforation and fungal keratitis[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2024, 14(02): 95-101.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2024.02.006

https://zhykyxzz.cma-cmc.com.cn/EN/Y2024/V14/I02/95

Figures/Tables 4

References 79

[1]	苗恒，陶勇，黎晓新. 重视眼部移植物抗宿主病的诊断和治疗[J]. 中华眼科医学杂志(电子版)，2014，4(1)：1－6.
[2]	Ferrara JL, Levine JE, Reddy P, et al. Graft－versus－host disease[J]. The Lancet, 2009, 373(9674): 1550－1561.
[3]	Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft－versus－host disease: I. Diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005, 11(12): 945－956.
[4]	Zeiser R, Blazar BR. Acute graft－versus－host disease——biologic process, prevention, and therapy[J]. N Engl J Med, 2017, 377(22): 2167－2179.
[5]	Malard F, Holler E, Sandmaier BM, et al. Acute graft－versus－host disease[J]. Nat Rev Dis Primers, 2023, 9(1): 27.
[6]	Baumrin E, Loren AW, Falk SJ, et al. Chronic graft－versus－host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations[J]. J Am Acad Dermatol, 2024, 90(1): 1－16.
[7]	Liu YC, Gau JP, Lin PY, et al. Conjunctival acute graft－versus－host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation: a cohort study[J]. PLoS One, 2016, 11(11): e167129.
[8]	Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation: Ⅰ. clinical study[J]. Arch Ophthalmol, 1983, 101(4): 580－584.
[9]	Saito T, Shinagawa K, Takenaka K, et al. Ocular manifestation of acute graft－versus－host disease after allogeneic peripheral blood stem cell transplantation[J]. Int J Hematol, 2002, 75(3): 332－334.
[10]	Uchino M, Ogawa Y, Kawai M, et al. Ocular complications in a child with acute graft－versus－host disease following cord blood stem cell transplantation: therapeutic challenges[J]. Acta Ophthalmol Scand, 2006, 84(4): 545－548.
[11]	Hayashi S, Shimizu E, Uchino M, et al. The overlap syndrome: a case report of chronic graft－versus－host disease after the development of a pseudomembrane[J]. Cornea, 2021, 40(9): 1188－1192.
[12]	Soleimani M, Mahdavi SP, Cheraqpour K, et al. Ocular graft－versus－host disease (oGVHD): From A to Z[J]. Surv Ophthalmol, 2023, 68(4): 697－712.
[13]	Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft－versus－host disease[J]. Bone Marrow Transplant, 2004, 33(10): 1031－1035.
[14]	Nair S, Vanathi M, Mukhija R, et al. Update on ocular graft－versus－host disease[J]. Indian J Ophthalmol, 2021, 69(5): 1038－1050.
[15]	Kim SK, Couriel D, Ghosh S, et al. Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD[J]. Biol Blood Marrow Transplant, 2006, 12(2): 49－50.
[16]	Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD[J]. Invest Ophthalmol Vis Sci, 2001, 42(1): 111－119.
[17]	Zhao W, Yang J, Liao Y, et al. Comparable meibomian gland changes in patients with and without ocular graft－versus－host disease after hematopoietic stem cell transplantation[J]. Ocul Surf, 2022, 25: 1－7.
[18]	Choi W, Ha JY, Li Y, et al. Comparison of the meibomian gland dysfunction in patients with chronic ocular graft－versus－host disease and Sjögren′s syndrome[J]. Int J Ophthalmol, 2019, 12(3): 393－400.
[19]	Engel LA, Wittig S, Bock F, et al. Meibography and meibomian gland measurements in ocular graft－versus－host disease[J]. Bone Marrow Transplant, 2015, 50(7): 961－967.
[20]	Hettinga YM, Verdonck LF, Fijnheer R, et al. Anterior uveitis: a manifestation of graft－versus－host disease[J]. Ophthalmology, 2007, 114(4): 794－797.
[21]	Lin CY, Chien HJ. Acute exacerbation of ocular graft－versus－host disease and anterior uveitis after COVID－19 vaccination[J]. BMC Ophthalmol, 2023, 23(1): 360.
[22]	Kaiserman I, Or R. Laser photocoagulation for central serous retinopathy associated with graft－versus－host disease[J]. Ocul Immunol Inflamm, 2005, 13(2－3): 249－256.
[23]	Xu Y, Wang YM, Sun ZT, et al. Corneal perforation associated with ocular graft－versus－host disease[J]. Front Oncol, 2022, 12: 962250.
[24]	Inagaki E, Ogawa Y, Matsumoto Y, et al. Four cases of corneal perforation in patients with chronic graft－versus－host disease[J]. Mol Vis, 2011, 17: 598－606.
[25]	Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation[J]. Ocul Surf, 2005, 3(4): 203－211.
[26]	Tabbara KF, Al－Ghamdi A, Al－Mohareb F, et al. Ocular Findings after Allogeneic Hematopoietic Stem Cell Transplantation[J]. Ophthalmology, 2009, 116(9): 1624－1629.
[27]	Sinha S, Singh RB, Dohlman TH, et al. Prevalence of persistent corneal epithelial defects in chronic ocular graft－versus－host disease[J]. Am J Ophthalmol, 2020, 218: 296－303.
[28]	Sepulveda－Beltran PA, Carletti P, Banda V, et al. Infectious and noninfectious corneal ulcers in ocular graft－versus－host disease: epidemiology, clinical characteristics, and outcomes[J]. Am J Ophthalmol, 2024, 257: 236－246.
[29]	Ogawa Y, Shimmura S, Kawakita T, et al. Epithelial mesenchymal transition in human ocular chronic graft－versus－host disease[J]. Am J Pathol, 2009, 175(6): 2372－2381.
[30]	Ogawa Y, Kawakami Y, Tsubota K. Cascade of inflammatory, fibrotic processes, and stress－induced senescence in chronic GVHD－related dry eye disease[J]. Int J Mol Sci, 2021, 22(11): 6114.
[31]	Dietrich－Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft－versus－host disease: report from the German－Austrian－Swiss Consensus Conference on Clinical Practice in chronic GVHD[J]. Cornea, 2012, 31(3): 299－310.
[32]	Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review[J]. Ophthalmic Physiol Opt, 2009, 29(6): 573－583.
[33]	Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome[J]. Am J Ophthalmol, 2001, 131(1): 30－36.
[34]	Wang Y, Carreno－Galeano JT, Singh RB, et al. Long－term outcomes of punctal cauterization in the management of ocular surface diseases[J]. Cornea, 2021, 40(2): 168－171.
[35]	Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta－analysis[J]. Ocul Surf, 2015, 13(3): 213－225.
[36]	Lelli GJ, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD[J]. Cornea, 2006, 25(6): 635－638.
[37]	Asena L, Dursun AD. Application of topical 2% cyclosporine A in inflammatory ocular surface diseases[J]. Int Ophthalmol, 2023, 43(11): 3943－3952.
[38]	Barber LD, Pflugfelder SC, Tauber J, et al. Phase Ⅲ safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years[J]. Ophthalmology, 2005, 112(10): 1790－1794.
[39]	Abud TB, Amparo F, Saboo US, et al. A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft－versus－host disease[J]. Ophthalmology, 2016, 123(7): 1449－1457.
[40]	Espana EM, Shah S, Santhiago MR, et al. Graft versus host disease: clinical evaluation, diagnosis and management[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(5): 1257－1266.
[41]	Jung JW, Lee YJ, Yoon SC, et al. Long－term result of maintenance treatment with tacrolimus ointment in chronic ocular graft－versus－host disease[J]. Am J Ophthalmol, 2015, 159(3): 519－527.
[42]	刘姝婉，赵英涵，马骄，等. 0.05%环孢素A与0.1%他克莫司滴眼液治疗cGVHD相关重度干眼的疗效评价[J]. 中华眼科杂志，2023，59(10)：805－813.
[43]	Townley JR, Dana R, Jacobs DS. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment[J]. Semin Ophthalmol, 2011, 26(4－5): 251－260.
[44]	Yin J, Kheirkhah A, Dohlman T, et al. Reduced efficacy of low－dose topical steroids in dry eye disease associated with graft－versus－host disease[J]. Am J Ophthalmol, 2018, 190: 17－23.
[45]	Tahmaz V, Gehlsen U, Sauerbier L, et al. Treatment of severe chronic ocular graft－versus－host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study[J]. Br J Ophthalmol, 2017, 101(3): 322－326.
[46]	Tahmaz V, Wiesen M, Gehlsen U, et al. Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease[J]. Graefes Arch Clin Exp Ophthalmol, 2021, 259(1): 121－128.
[47]	Chaudhary S, Ghimire D, Basu S, et al. Contact lenses in dry eye disease and associated ocular surface disorders[J]. Indian J Ophthalmol, 2023, 71(4): 1142－1153.
[48]	Bligdon SM, Colarusso BA, Ganjei AY, et al. Scleral lens and prosthetic replacement of the ocular surface ecosystem utilization in ocular graft－versus－host disease: a survey study[J]. Clin Ophthalmol, 2021, 15: 4829－4838.
[49]	Peris－Martínez C, Menezo JL, Díaz－Llopis M, et al. Multilayer amniotic membrane transplantation in severe ocular graft versus host disease[J]. Eur J Ophthalmol, 2001, 11(2): 183－186.
[50]	Yin HY, Dhanireddy S, Weisenthal R, et al. Self－retained cryopreserved amniotic membrane in treating acute ocular graft－versus－host－disease (oGVHD)[J]. Am J Ophthalmol Case Rep, 2020, 19: 100761.
[51]	Heath JD, Acheson JF, Schulenburg WE. Penetrating keratoplasty in severe ocular graft versus host disease[J]. Br J Ophthalmol, 1993, 77(8): 525－526.
[52]	Pellegrini M, Bernabei F, Barbato F, et al. Incidence, risk factors and complications of ocular graft－versus－host disease following hematopoietic stem cell transplantation[J]. Am J Ophthalmol, 2021, 227: 25－34.
[53]	Stevenson W, Shikari H, Saboo US, et al. Bilateral corneal ulceration in ocular graft－versus－host disease[J]. Clin Ophthalmol, 2013, 7: 2153－2158.
[54]	Lin X, Cavanagh HD. Ocular manifestations of graft－versus－host disease: 10 years′ experience[J]. Clin Ophthalmol, 2015, 9: 1209－1213.
[55]	Adrean SD, Puklin JE. Perforated corneal ulcer with subsequent endophthalmitis in a patient with graft－versus－host disease[J]. Cornea, 2007, 26(1): 107－108.
[56]	Mohammadpour M, Maleki S, Hashemi H, et al. Recurrent corneal perforation due to chronic graft versus host disease; a clinicopathologic report[J]. J Ophthalmic Vis Res, 2016, 11(1): 108－111.
[57]	Yeh PT, Hou YC, Lin WC, et al. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft－versus－host disease[J]. J Formos Med Assoc, 2006, 105(4): 334－339.
[58]	Shikari H, Antin JH, Dana R. Ocular graft－versus－host disease: a review[J]. Surv Ophthalmol, 2013, 58(3): 233－251.
[59]	Zhang CY, Farooq AV, Harocopos GJ, et al. Corneal perforation in ocular graft－versus－host disease[J]. Am J Ophthalmol Case Rep, 2021, 24: 101224.
[60]	Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjögren′s syndrome[J]. Arch Ophthalmol, 1980, 98(1): 89－94.
[61]	Suzuki M, Usui T, Kinoshita N, et al. A case of sterile corneal perforation after bone marrow transplantation[J]. Eye (Lond), 2007, 21(1): 114－116.
[62]	Webster RJ, Slansky HH, Refojo MF, et al. The use of adhesive for the closure of corneal perforations. Report of two cases[J]. Arch Ophthalmol, 1968, 80(6): 705－709.
[63]	Weiss JL, Williams P, Lindstrom RL, et al. The use of tissue adhesive in corneal perforations[J]. Ophthalmology, 1983, 90(6): 610－615.
[64]	Leahey AB, Gottsch JD, Stark WJ. Clinical experience with N－butyl cyanoacrylate (Nexacryl) tissue adhesive[J]. Ophthalmology, 1993, 100(2): 173－180.
[65]	Moschos M, Droutsas D, Boussalis P, et al. Clinical experience with cyanoacrylate tissue adhesive[J]. Doc Ophthalmol, 1996, 93(3): 237－245.
[66]	Yin J, Singh RB, Al KR, et al. Outcomes of cyanoacrylate tissue adhesive application in corneal thinning and perforation[J]. Cornea, 2019, 38(6): 668－673.
[67]	Sharma A, Kaur R, Kumar S, et al. Fibrin glue versus N－butyl－2－cyanoacrylate in corneal perforations[J]. Ophthalmology, 2003, 110(2): 291－298.
[68]	Carlson AN, Wilhelmus KR. Giant papillary conjunctivitis associated with cyanoacrylate glue[J]. Am J Ophthalmol, 1987, 104(4): 437－438.
[69]	Ferry AP, Barnert AH. Granulomatous keratitis resulting from use of cyanoacrylate adhesive for closure of perforated corneal ulcer[J]. Am J Ophthalmol, 1971, 72(3): 538－541.
[70]	Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers[J]. Br J Ophthalmol, 2000, 84(8): 826－833.
[71]	Hanada K, Shimazaki J, Shimmura S, et al. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera[J]. Am J Ophthalmol, 2001, 131(3): 324－331.
[72]	Sanders F, Huang J, Alió DBJ, et al. Amniotic membrane transplantation: structural and biological properties, tissue preparation, application and clinical indications[J]. Eye (Lond), 2024, 38(4): 668－679.
[73]	Deshmukh R, Stevenson LJ, Vajpayee R. Management of corneal perforations: An update[J]. Indian J Ophthalmol, 2020, 68(1): 7－14.
[74]	Chan E, Shah AN, O′Brart DP. "Swiss roll" amniotic membrane technique for the management of corneal perforations[J]. Cornea, 2011, 30(7): 838－841.
[75]	Akle CA, Adinolfi M, Welsh KI, et al. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers[J]. Lancet, 1981, 2(8254): 1003－1005.
[76]	Namba H, Narumi M, Nishi K, et al. "Pleats fold" technique of amniotic membrane transplantation for management of corneal perforations[J]. Cornea, 2014, 33(6): 653－657.
[77]	Mannis MJ, Holland EJ, Gal RL, et al. The effect of donor age on penetrating keratoplasty for endothelial disease: graft survival after 10 years in the Cornea Donor Study[J]. Ophthalmology, 2013, 120(12): 2419－2427.
[78]	Watson SL, Ramsay A, Dart JK, et al. Comparison of deep lamellar keratoplasty and penetrating keratoplasty in patients with keratoconus[J]. Ophthalmology, 2004, 111(9): 1676－1682.
[79]	Cui Y, Xiao X, Hu J. Safety and Efficacy of double lamellar keratoplasty for corneal perforation[J]. Ophthalmol Ther, 2023, 12(2): 1251－1262.

级别	临床表现
1级	仅结膜充血
2级	结膜充血伴浆液性渗出
3级	伪膜性结膜炎
4级	伪膜性结膜炎伴角膜上皮损伤

级别	临床表现
1级	仅结膜充血
2级	结膜充血伴浆液性渗出
3级	伪膜性结膜炎
4级	伪膜性结膜炎伴角膜上皮损伤

级别	结膜病变表现
1级	球结膜充血或至少一处眼睑结膜充血
2级	至少一处睑结膜出现25%以内面积的纤维血管改变、伴或不伴结膜上皮脱落
3级	至少一处睑结膜出现25%～75%面积的纤维血管改变
4级	至少一处睑结膜出现75%以上面积的纤维血管改变，伴或不伴瘢痕性睑内翻

级别	结膜病变表现
1级	球结膜充血或至少一处眼睑结膜充血
2级	至少一处睑结膜出现25%以内面积的纤维血管改变、伴或不伴结膜上皮脱落
3级	至少一处睑结膜出现25%～75%面积的纤维血管改变
4级	至少一处睑结膜出现75%以上面积的纤维血管改变，伴或不伴瘢痕性睑内翻

第一作者	年份(年)	例数(只眼)	主要病菌	主要治疗
Pellegrini等^[52]	2007	2(2)		角膜移植
Stevenson等^[53]	2013	2(2)		角膜移植联合广谱抗生素
Lin等^[54]	2015	3(3)		绷带镜和组织粘合剂
Sean等^[55]	2007	1(1)	表皮葡萄球菌	继发眼内炎和玻璃体切割术
Mohammadpour等^[56]	2016	1(1)		组织粘合剂、多层羊膜及角膜移植
Yeh等^[57]	2006	1(1)		多次角膜移植、羊膜覆盖及睑缘缝合
Zhang等^[58]	2021	14(14)		睑缘缝合、角膜移植及眼球摘除
Xu等^[23]	2022	7(7)		羊膜移植、角膜移植及结膜瓣覆盖

Please choose a citation manager

Content to export

One case of eye graft-versus-host disease with corneal perforation and fungal keratitis

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 79

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

One case of eye graft-versus-host disease with corneal perforation and fungal keratitis

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 79

Related Articles 0

Recommended Articles

Metrics

Comments